The trial of former Theranos executive Elizabeth Holmes, set to begin Aug. 31, is sure to highlight a sore point in the history of Boies Schiller Flexner and its founder David Boies.
Boies’ representation of Holmes, and the optics surrounding the spectacular collapse of the company in 2018, was a contributing factor in the cascade of departures the law firm experienced in 2020, according to several former partners at the firm—even as some in and outside of the firm say Boies did nothing wrong throughout the episode.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Why am I seeing this?
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM’s legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM’s content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]